Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Investigating the potential of BCMA CAR-T therapies in AL Amyloidosis, including NXC-201 by Immix Biopharma/Nexcella

Ticker(s): IMMX, BMY, JNJ

Who's the expert?

Institution: Memorial Sloan Kettering Cancer Center

Attending physician on the adult BMT service at Memorial Sloan Kettering Cancer Center with an expertise in the treatment of patients with plasma cell dyscrasias including multiple myeloma (MM) and light chain (AL) amyloidosis.
Currently treats ~50 patients with AL amyloidosis and very familiar with the literature to date for NEOD001.
Has served as PI on multiple trials and currently working with the Amyloid Research Consortium to develop a draft guidance for the FDA with hope of accelerating drug development in AL amyloidosis.

Interview Goal

This call would discuss the efficacy, safety, and clinical implications of BCMA CAR-T therapy, including NXC-201 from the NEXICART-2 trial by Immix Biopharma and Nexcella, for treating AL amyloidosis, focusing on hematologic and organ response rates.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.